Some things come to my mind in this minute: [this post is not intended to reply to fox, sorry]
nwbo trial registry has not been updated since Oct 2016, even after the partial halt for new patient screen was lifted by FDA in early 2017
if lifting of a halt has been ignored why this revised endpoints?
Personally I don't want to have anything be documented and later find it may hinder flexibility in dealing with FDA as FDA is such a rigid beast
All signs points to positive outcome of the trial, hereby the company, its investors, and most importantly for GBM patients -- no distraction from the company to launch new trials, or buying a tiny biotech to expand pipelines,
No major shareholders and insiders have cashed in, leaving huge mountain high, ocean deep derivatives and shares intact....
All in all not much of a fanfare for anything [expanding patents, manufacturing progress,...], but deafening quietness!
News 
Market Data 
Discover 
AI
